Shanxian Granule Serum Suppresses Hepatic Oval Cell Malignant Transformation by Targeting the Wnt/β-Catenin Pathway

Mengyang Qu; Yanfang Pan; Lei Niu

doi:10.54097/1xdy9574

Authors

Mengyang Qu
Yanfang Pan
Lei Niu

DOI:

https://doi.org/10.54097/1xdy9574

Keywords:

Shanxian granule‑containing Serum, Precancerous Lesions of Liver, Wnt/β-catenin Signaling Pathway, Hepatic Oval Cells

Abstract

Aim In this study, we aimed to investigate how SXG serum attenuates the malignant phenotype in HOC. Methods Rat hepatic oval cells (HOC), WB-F344 was induced to undergo malignant transformation using N-methyl-N'-nitro-N-nitroso (MNNG). MNNG-treated WB-F344 cells were administered dose-dependent levels (low/medium/high) SXG-containing serum to evaluate its inhibitory effects. To examine pathway involvement, the Wnt agonist CP21R7 was co-administered with high-dose SXG serum. Cellular proliferation was quantified by MTT assay, while Wnt/β-catenin pathway components (wnt3a, β-catenin, C-Myc) were analyzed at mRNA levels using qPCR. Results Compared with the normal group, the Model showed a significantly enhanced cell proliferation capacity (P<0.05). Relative to the Model, the experimental group exhibited a significant decrease in cell proliferation (P<0.05). Moreover, SXG-containing serum significantly downregulated wnt3a β-catenin and C-Myc expression. which are important components of the Wnt/β-catenin signaling pathway and CP21R7 can antagonize the SXG effect (P<0.05). Conclusion SXG inhibits oncogenic transformation of WB-F344 cells by suppressing the Wnt/β-catenin pathway.

Downloads

Download data is not yet available.

References

[1] Balogh J, Victor III D, Asham EH, et al. Hepatocellular carcinoma: a review. Journal of hepatocellular carcinoma 2016; 3: 41.

[2] Wang G, Wang Q, Liang N, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell death & disease 2020;11(5):313.

[3] Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma. Cancers 2019; 11(11):1704.

[4] Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology (Baltimore, Md) 2007; 45(1):968-76.

[5] Pan Y, Jia X, Ying X, et al. Shanxian granule ameliorates diethylnitrosamine-induced precancerous lesions in liver by regulating inflammatory mediators[C]//E3S Web of Conferences. EDP Sciences 2020, 185:03020.

[6] Bi YH, Han WQ, Li RF, Wang YJ, Jiang Y. Signal transducer and activator of transcription 3 promotes the Warburg effect possibly by inducing pyruvate kinase M2 phosphorylation in liver precancerous lesions. World journal of gastroenterology 2019; 25(16):1936-1949.

[7] Ding L, Ding YN, Lin Y, Wen JM, Xue L. Proteins related to early changes in carcinogenesis of hepatic oval cells after treatment with methylnitronitrosoguanidine. Experimental and Toxicologic Pathology 2014;66(2-3):139-46.

[8] Chen L, Zhang W, Liang H-f, et al. Activin A induces growth arrest through a SMAD-dependent pathway in hepatic progenitor cells. Cell Communication and Signaling 2014; 12: 1-14.

[9] Qu M-y, Pan Y-f, Xie M, editors. Research progress of intestinal microecology in the occurrence and development of precancerous lesions of liver[C]//E3S Web of Conferences. EDP Sciences 2021, 251:02046.

[10] Thoppil RJ, Harlev E, Mandal A, Nevo E, Bishayee A. Antitumor activities of extracts from selected desert plants against HepG2 human hepatocellular carcinoma cells. Pharmaceutical Biology 2013;51(5):668-74.

[11] Tang W, Xue J, Luo L, et al. Kangxianruangan granule-containing serum mediated inhibition of hepatic oval cell differentiation into hepatocellular carcinoma cells via the Wnt-1/β-catenin signaling pathway. Molecular medicine reports 2022; 25(2):55.

[12] Thompson M D, Monga S P S.WNT/beta-catenin signaling in liver health and disease.Hepatology 2010, 45(5):1298-1305.

[13] Pashirzad M, Fiuji H, Khazei M, Moradi-Binabaj M, Hassanian SM. Role of Wnt3a in the pathogenesis of cancer, current status and prospective. Molecular Biology Reports 2019; 46(5):5609-5616.

[14] Lei T, Zhu X, Zhu K, et al. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway. Cancer Biol Ther 2019;20(7):1007-1016.

[15] Jin X, Yin J, Zhu H, et al. SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma. Frontiers in pharmacology 2021; 12:701454.

[16] Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology 2017; 152(4):745-61.